BiomarkersPub Date : 2024-03-01Epub Date: 2024-02-27DOI: 10.1080/1354750X.2024.2319297
Marina Dunaeva, Jan Blom, Rogier Thurlings, Margot van Weijsten, Fons A J van de Loo, Ger J M Pruijn
{"title":"Circulating tRNA-derived fragments are decreased in patients with rheumatoid arthritis and increased in patients with psoriatic arthritis.","authors":"Marina Dunaeva, Jan Blom, Rogier Thurlings, Margot van Weijsten, Fons A J van de Loo, Ger J M Pruijn","doi":"10.1080/1354750X.2024.2319297","DOIUrl":"10.1080/1354750X.2024.2319297","url":null,"abstract":"<p><strong>Introduction: </strong>tRNA-derived fragments (tRFs) play an important role in immune responses. To clarify the role of tRFs in autoimmunity we studied circulating tRF-levels in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA), and in a murine model for arthritis.</p><p><strong>Material and methods: </strong>Circulating tRF-levels were quantified by miR-Q RT-qPCR. tRNA processing and modification enzyme expression was analysed by RT-qPCR and public transcriptomics data.</p><p><strong>Results: </strong>Significant reduction (up to 3-fold on average) of tRF-levels derived from tRNA-Gly-GCC,CCC, tRNA-Glu-CTC and tRNA-Val-CAC,AAC was observed in RA patients, whereas tRNA-Glu-CTC and tRNA-Val-CAC,AAC tRFs were found at significantly higher levels (up to 3-fold on average) in PsA patients, compared to healthy controls. Also in arthritic IL1Ra-KO mice reduced levels of tRNA-Glu-CTC fragments were seen. The expression of NSUN2, a methyltransferase catalysing tRNA methylation, was increased in RA-peripheral blood mononuclear cells (PBMCs) compared to PsA, but this is not consistently supported by public transcriptomics data.</p><p><strong>Discussion: </strong>The observed changes of specific tRF-levels may be involved in the immune responses in RA and PsA and may be applicable as new biomarkers.</p><p><strong>Conclusion: </strong>Circulating tRF-levels are decreased in RA and increased in PsA and this may, at least in part, be mediated by methylation changes.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"90-99"},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139740295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Protein kinase C delta enhances the diagnostic performance of hepatocellular carcinoma.","authors":"Chika Nakagawa, Tsunekazu Oikawa, Kohji Yamada, Akihito Tsubota, Chisato Saeki, Kuniko Katagiri, Naoko Tago, Hiroshi Kamioka, Kaoru Ueda, Koichiro Haruki, Kenei Furukawa, Masanori Nakano, Yuichi Torisu, Toru Ikegami, Kiyotsugu Yoshida, Masayuki Saruta","doi":"10.1080/1354750X.2024.2312990","DOIUrl":"10.1080/1354750X.2024.2312990","url":null,"abstract":"<p><strong>Background: </strong>The conventional markers for hepatocellular carcinoma (HCC), α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP), have several limitations; both have low sensitivity in patients with early-stage HCC; low sensitivity for AFP with HCC after eliminating hepatitis C virus (HCV); low specificity for DCP in patients with non-viral HCC, which is increasing worldwide; low specificity for AFP in patients with liver injury; and low specificity for DCP in patients treated with warfarin. To overcome these issues, the identification of novel biomarkers is an unmet need.</p><p><strong>Objective: </strong>This study aimed to assess the usefulness of serum protein kinase C delta (PKCδ) for detecting these HCCs.</p><p><strong>Methods: </strong>PKCδ levels were measured using a sandwich enzyme-linked immunosorbent assay in 363 chronic liver disease (CLD) patients with and without HCC.</p><p><strong>Results: </strong>In both viral and non-viral CLD, PKCδ can detect HCCs with high sensitivity and specificity, particularly in the very early stages. Notably, the value and sensitivity of PKCδ were not modified by HCV elimination status. Liver injury and warfarin administration, which are known to cause false-positive results for conventional markers, did not modify PKCδ levels.</p><p><strong>Conclusions: </strong>PKCδ is an enhanced biomarker for the diagnosis of HCC that compensates for the drawbacks of conventional markers.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"55-67"},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139740296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BiomarkersPub Date : 2024-03-01Epub Date: 2024-02-27DOI: 10.1080/1354750X.2024.2319308
Alan H B Wu, Chia-Ching Wang
{"title":"Serum free light chains among twin siblings: is the kappa/lambda ratio genetically determined?","authors":"Alan H B Wu, Chia-Ching Wang","doi":"10.1080/1354750X.2024.2319308","DOIUrl":"10.1080/1354750X.2024.2319308","url":null,"abstract":"<p><strong>Background: </strong>Serum kappa, lambda, the K/λ light chain concentrations are used for screening, diagnosis, and monitoring of patients with multiple myeloma and other plasma cell disorders. Biological variation studies conducted on healthy subjects showed that free light chains have a low within and high between-individual variation. We determined if this variation were genetically linked.</p><p><strong>Methods: </strong>We obtained a single serum sample from 16 pairs of identical twins, 8 neonate twins, and 19 presumed directly-related siblings children, measured Κ and λ light chains and computed the Κ/λ ratio.</p><p><strong>Results: </strong>As expected, Κ/λ results from each twin neonate were near identical (reflecting maternal/placental transfer). For older children and adult twins, the Κ/λ ratio form a cluster of results that were a subset of the reference range. There was one outlier, a female with a high, different from her twin sister. She likely had a monoclonal gammopathy (no followup was possible). Excluding this pair, results from neonate twins (14.4% ±10.3%) and non-neonate twins (18.0 ± 15.3%) were not significantly different. Results between non-twin siblings were more scattered (53.2%±53.4%) and different from neonate and non-neonate twin adult and children.</p><p><strong>Conclusion: </strong>We suggest that the Κ/λ free light chains may be genetically linked.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"100-104"},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139728854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Subchronic exposure to fenpyroximate causes multiorgan toxicity in Wistar rats by disrupting lipid profile, inducing oxidative stress and DNA damage.","authors":"Imen Ayed-Boussema, Karima Rjiba, Asma M'nassri, Hiba Hamdi, Salwa Abid","doi":"10.1080/1354750X.2024.2313663","DOIUrl":"10.1080/1354750X.2024.2313663","url":null,"abstract":"<p><strong>Background: </strong>Fenpyroximate (FEN) is an acaricide that inhibits the complex I of the mitochondrial respiratory chain in mites. Data concerning mammalian toxicity of this acaricide are limited; thus the aim of this work was to explore FEN toxicity on Wistar rats, particularly on cardiac, pulmonary, and splenic tissues and in bone marrow cells.</p><p><strong>Methods: </strong>rats were treated orally with FEN at 1, 2, 4, and 8 mg/Kg bw for 28 days. After treatment, we analyzed lipid profile, oxidative stress and DNA damage in rat tissues.</p><p><strong>Results: </strong>FEN exposure increased creatinine phosphokinase (CPK) and lactate dehydrogenase (LDH) activities, elevated total cholesterol (T-CHOL), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) concentrations, while decreasing high-density lipoprotein cholesterol (HDL-C). It inhibited acetylcholinesterase (AChE) activity, enhanced lipid peroxidation, protein oxidation, and modulated antioxidant enzymes activities (superoxide dismutase, catalase, glutathione peroxidase, and glutathione S-transferase). Comet assay indicated that FEN induced a dose-dependent DNA damage, contrasting with the micronucleus test showing no micronuclei formation. Nonetheless, FEN exhibited cytotoxicity to bone marrow cells, as evidenced by a reduction in the number of immature erythrocytes among total cells.</p><p><strong>Conclusion: </strong>FEN appears to carry out its genotoxic and cytotoxic activities most likely through an indirect pathway that involves oxidative stress.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"68-77"},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139650265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BiomarkersPub Date : 2024-03-01Epub Date: 2024-02-29DOI: 10.1080/1354750X.2024.2319702
Yu Song, Haibo Li, Qing Jiang, Lianghong Wu
{"title":"Prognostic and clinicopathological value of osteopontin expression in non-small cell lung cancer: a meta-analysis and systematic review.","authors":"Yu Song, Haibo Li, Qing Jiang, Lianghong Wu","doi":"10.1080/1354750X.2024.2319702","DOIUrl":"10.1080/1354750X.2024.2319702","url":null,"abstract":"<p><strong>Background: </strong>Although Osteopontin (OPN) has been reported to be associated with many different human cancers, the data on non-small cell lung cancer (NSCLC) are not definitive. This study aimed to explore the prognostic effect of OPN expression and clinicopathological characteristics in patients with NSCLC.</p><p><strong>Methods: </strong>This study followed all aspects of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) report. PubMed, Embase and the Cochrane Library were searched to identify the relative studies. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to estimate the prognostic value of the OPN in patients with NSCLC. The odds ratio (OR) was calculated to represent the relationship between OPN expression and clinicopathological parameters.</p><p><strong>Results: </strong>A total of fifteen studies with 2173 participants were finally included. The results revealed that high expression of OPN was significantly associated with poorer overall survival (OS) (HR = 1.89; 95%CI = 1.68-2.11; p < 0.001). Moreover, a significant correlation was observed between increased OPN expression and poorly differentiated (well and moderately differentiated vs. poorly differentiated; pooled OR = 0.38; 95% CI = 0.23-0.64; p < 0.001), lymph node metastasis (absence vs. presence; pooled OR = 0.49; 95%CI = 0.32-0.74; p < 0.001), and distant metastasis (absence vs. presence; pooled OR = 0.18; 95%CI = 0.11-0.29; p < 0.001).</p><p><strong>Conclusion: </strong>This meta-analysis implies that OPN might be a valuable biomarker for a poor prognosis and poor clinicopathological outcomes for patients with NSCLC.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"105-113"},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139904979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"<i>Phœnix dactylifera,</i> L. seed oil alleviates Bleomycin-induced pulmonary fibrosis and oxidative stress in <i>Wistar</i> rats.","authors":"Sana Bahri, Raed Abdennabi, Asma Chaker, Afef Nahdi, Amine Elgheryeni, Mona Mlika, Saloua Jameleddine","doi":"10.1080/1354750X.2024.2311178","DOIUrl":"10.1080/1354750X.2024.2311178","url":null,"abstract":"<p><strong>Objective: </strong>Idiopathic pulmonary fibrosis (IPF) is the most serious form of interstitial lung disease. We aimed to investigate the effect of <i>Phœnix dactylifera, L.</i> seed oil (DSO) on a murine model of IPF induced by bleomycin (BLM).</p><p><strong>Methods: </strong>Male Wistar rats were treated with a single intra-tracheal injection of BLM (4 mg/kg) and a daily intraperitoneal injection of DSO (75, 150 and 300 mg/kg) for 4 weeks.</p><p><strong>Results: </strong>Our phytochemical results showed that DSO has an important antioxidant activity with a high content of polyphenols and flavonoids. High-Performance Liquid Chromatography (HPLC) and Gas chromatography/mass spectrometry (GC-MS) analysis revealed a high amount of oleic and lauric acids and a large quantity of vitamins. Histological examination showed a significant reduction in fibrosis score and collagen bands in the group of rats treated with 75 mg/kg of DSO compared to the BLM group. DSO (75 mg/kg) reversed also the increase in catalase and malondialdehyde (MDA) levels while higher doses (150 and 300 mg/kg) are ineffective against the deleterious effects of BLM. We revealed also that DSO has no renal or hepatic cytotoxic effects.</p><p><strong>Conclusion: </strong>DSO can play antioxidant and antifibrotic effects on rat models of pulmonary fibrosis at the lowest dose administered.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"45-54"},"PeriodicalIF":2.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139680639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BiomarkersPub Date : 2024-02-01Epub Date: 2024-02-12DOI: 10.1080/1354750X.2024.2304187
Narges Jafarbeik-Iravani, Sara Kolahdozan, Rezvan Esmaeili
{"title":"The role of ASXL1 mutations and ASXL1 CircRNAs in cancer.","authors":"Narges Jafarbeik-Iravani, Sara Kolahdozan, Rezvan Esmaeili","doi":"10.1080/1354750X.2024.2304187","DOIUrl":"10.1080/1354750X.2024.2304187","url":null,"abstract":"<p><strong>Background: </strong>Mutations in the Additional Sex Combs Like 1 (<i>ASXL1</i>) gene were first reported in myelodysplastic syndromes. Recent studies have clarified the relationship between <i>ASXL1</i> mutations and the development of cancers.</p><p><strong>Objective: </strong>This study aims to review the roles of <i>ASXL1</i> and <i>ASXL1</i> CircRNAs, such as epigenetic regulation, chromatin modification, and transcription factor function in malignancies.</p><p><strong>Method: </strong>This study is a review of articles related to the role of <i>ASXL1</i> and <i>ASXL1</i> CircRNAs in malignancies, retrieved from PubMed and Scopus.</p><p><strong>Results: </strong><i>ASXL1</i> plays a role in malignancies and is also related to poor overall survival and cancer metastasis. <i>ASXL1</i> encodes conserved and abundant Circular RNAs (circRNAs) that act as post-transcriptional regulators, regulating tumorigenesis and progression in cancer. <i>ASXL1</i> circRNA was identified in the top 10% of differentially expressed circRNAs in clinically relevant tissues. Additionally, the role of <i>ASXL1</i> gene circRNAs in cancer development is reviewed in this study.</p><p><strong>Conclusion: </strong><i>ASXL1</i> and <i>ASXL1</i>circRNA have dual functions in combination with different proteins, being involved in both transcriptional activation and repression in a context-dependent manner. Moreover, studies indicate these genes play an important role in epithelial-mesenchymal transition (EMT) and metastasis. Ongoing research is aimed at determining this gene family's function in biological events.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-6"},"PeriodicalIF":2.6,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139401658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Deciphering the potential of proteomic-based biomarkers in women's reproductive diseases: empowering precision medicine in gynecology.","authors":"Ishwerpreet Kaur Jawanda, Thomson Soni, Seema Kumari, Vijay Prabha","doi":"10.1080/1354750X.2024.2308827","DOIUrl":"10.1080/1354750X.2024.2308827","url":null,"abstract":"<p><strong>Context: </strong>Gynecological disorders represent a complex set of malignancies that result from a diverse array of molecular changes affecting the lives of over a million women worldwide. Ovarian, Endometrial, and Cervical cancers, Endometriosis, PCOS are the most prevalent ones that pose a grave threat to women's health. Proteomics has emerged as an invaluable tool for developing novel biomarkers, screening methods, and targeted therapeutic agents for gynecological disorders. Some of these biomarkers have been approved by the FDA, but regrettably, they have a constrained diagnostic accuracy in early-stage diagnosis as all of these biomarkers lack sensitivity and specificity. Lately, high-throughput proteomics technologies have made significant strides, allowing for identification of potential biomarkers with improved sensitivity and specificity. However, limited successes have been shown with translation of these discoveries into clinical practice.</p><p><strong>Objective: </strong>This review aims to provide a comprehensive overview of the current and potential protein biomarkers for gynecological cancers, endometriosis and PCOS, discusses recent advances and challenges, and highlights future directions for the field.</p><p><strong>Conclusion: </strong>We propose that proteomics holds great promise as a powerful tool to revolutionize the fight against female reproductive diseases and can ultimately improve personalized patient outcomes in women's biomedicine.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"7-17"},"PeriodicalIF":2.6,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139511788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Assessing angiogenesis factors as prognostic biomarkers in breast cancer patients and their association with clinicopathological factors.","authors":"Tannaz Abbasi-Dokht, Farhad Malek, Nahid Nafissi, Maryam Mohammadlou, Maryam Sheikh, Sedigheh Akbari, Mohammad Hossein Zargaran, Rasoul Baharlou","doi":"10.1080/1354750X.2024.2309541","DOIUrl":"10.1080/1354750X.2024.2309541","url":null,"abstract":"<p><strong>Introduction: </strong>Angiogenesis is fundamental for tumor growth and metastasis across many solid malignancies. Considerable interest has focused on the molecular regulation of tumor angiogenesis as a means to predict disease outcomes and guide therapeutic decisions.</p><p><strong>Methods: </strong>In the present study, we investigated the prognostic value of transforming growth factor beta (TGF-β), epidermal growth factor (EGF), fibroblast growth factor (FGF), delta-like ligand 4 (DLL4), and vascular endothelial growth factor (VEGF) in the serum of 120 women diagnosed with breast cancer using ELISA as well as examined their associations with clinical parameters and the outcome of the disease.</p><p><strong>Results: </strong>Our results demonstrated that the serum concentration of TGF-β and EGF were remarkably higher in patients with higher tumor size, end stages of the disease, and positive lymph node involvement compared to patients with lower tumor size, early stages of the disease, and negative lymph node involvement. In addition, we found a significant correlation between the serum concentration of VEGF and the level of EGF, FGF, and DLL4 in patients with breast cancer. Furthermore, both univariate and multivariate analyses showed that TGF-β and EGF can be used as end-stage predictors.</p><p><strong>Discussion/conclusion: </strong>Based on our findings, increasing the level of angiogenesis factors is significantly associated with higher tumor size and late stages of the disease in patients with breast cancer. Moreover, measuring the level of angiogenesis factors could lead to better prediction of disease outcomes and choosing the best treatments for patients.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"36-43"},"PeriodicalIF":2.6,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139511813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Nucleosome assembly protein 1-like 1 (NAP1L1) in gastric cancer patients: a potential biomarker with diagnostic and prognostic utility.","authors":"Gungor Gul, Mehmet Akif Aydin, Sermin Algul, Remzi Kiziltan, Ozgur Kemik","doi":"10.1080/1354750X.2024.2309540","DOIUrl":"10.1080/1354750X.2024.2309540","url":null,"abstract":"<p><strong>Background: </strong>The nucleosome assembly protein 1-like 1 (NAP1L1) is suggested to have an oncogenic role in several tumors based on its overexpression. However, its diagnostic and prognostic role in gastric cancer remains unclarified. This study aimed to evaluate the diagnostic and prognostic utility of NAP1L1 in gastric cancer patients.</p><p><strong>Methods: </strong>A total of 85 patients [mean (<i>SD</i>) age: 60.9 (1.6) years, 49.4% were males] with newly-diagnosed gastric cancer and 40 healthy individuals [mean (<i>SD</i>) age: 60.7 (1.7) years, 52.5% were males] were included. Data on patient demographics (age, gender), TNM stages and tumor size, and the serum NAP1L1 levels were recorded.</p><p><strong>Results: </strong>Serum NAP1L1 levels were significantly higher in gastric cancer patients than in control subjects [12 (9.5-13.8) <i>vs.</i> 1.8 (1.5-2.4) ng/mL, <i>p</i> < 0.001]. Also, certain tumor characteristics such as tumor size of >4 <i>vs.</i> <4 cm (<i>p</i> < 0.001), M1 <i>vs.</i> M0 stage (<i>p</i> < 0.001), N2 <i>vs.</i> N0 and N1 stage (<i>p</i> < 0.001), and T4 <i>vs.</i> lower T stage (<i>p</i> < 0.001) were associated with significantly higher serum NAP1L1 levels in gastric cancer patients.</p><p><strong>Conclusions: </strong>Our findings revealed for the first time that serum levels for NAP1L1 were overexpressed in the gastric cancer, as also correlated with the disease progression. NAP1L1 seems to be a potential biomarker for gastric cancer, providing clinically important information on early diagnosis and risk stratification.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"30-35"},"PeriodicalIF":2.6,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139519922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}